SI1511770T1 - Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni - Google Patents
Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezniInfo
- Publication number
- SI1511770T1 SI1511770T1 SI200330640T SI200330640T SI1511770T1 SI 1511770 T1 SI1511770 T1 SI 1511770T1 SI 200330640 T SI200330640 T SI 200330640T SI 200330640 T SI200330640 T SI 200330640T SI 1511770 T1 SI1511770 T1 SI 1511770T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fusion protein
- glycoprotein
- treatment
- vascular diseases
- provides
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 102000003886 Glycoproteins Human genes 0.000 title abstract 2
- 108090000288 Glycoproteins Proteins 0.000 title abstract 2
- 208000019553 vascular disease Diseases 0.000 title 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02012742A EP1369128A1 (en) | 2002-06-07 | 2002-06-07 | Inhibitors of glycoprotein VI and their therapeutic use |
| EP03735562A EP1511770B1 (en) | 2002-06-07 | 2003-06-05 | Glycoprotein vi-fc fusion protein for the treatment of vascular diseases |
| PCT/EP2003/005929 WO2003104282A2 (en) | 2002-06-07 | 2003-06-05 | Immunoadhesin comprising a glycoprotein vi domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1511770T1 true SI1511770T1 (sl) | 2007-04-30 |
Family
ID=29433140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200330640T SI1511770T1 (sl) | 2002-06-07 | 2003-06-05 | Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7514543B2 (sl) |
| EP (4) | EP1369128A1 (sl) |
| JP (1) | JP4722480B2 (sl) |
| CN (1) | CN1668721B (sl) |
| AT (1) | ATE346095T1 (sl) |
| AU (2) | AU2003236704B2 (sl) |
| CA (1) | CA2488630C (sl) |
| DE (1) | DE60309865T2 (sl) |
| DK (1) | DK1860118T3 (sl) |
| ES (2) | ES2276078T3 (sl) |
| SI (1) | SI1511770T1 (sl) |
| WO (2) | WO2003104282A2 (sl) |
| ZA (1) | ZA200409776B (sl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061650A2 (en) * | 2004-12-10 | 2006-06-15 | Trigen Gmbh | Methods, products and uses involving platelets and/or the vasculature |
| GB0511590D0 (en) * | 2005-06-07 | 2005-07-13 | Procorde Gmbh | Anti-thrombotic agents |
| EP1369128A1 (en) | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| US7531178B2 (en) | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
| US20070071744A1 (en) | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
| US7645592B2 (en) | 2004-04-29 | 2010-01-12 | Otsuka Pharmaceutical Co., Ltd. | Glycoprotein VI antibodies and methods of use thereof |
| US7611707B2 (en) | 2004-04-29 | 2009-11-03 | Otsuka Pharmaceutical Co., Ltd. | Glycoprotein VI antibodies and methods thereof |
| CA2575607C (en) | 2004-08-03 | 2017-07-11 | Innate Pharma | Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor |
| FR2884831B1 (fr) * | 2005-04-22 | 2007-08-10 | Merck Sante Soc Par Actions Si | Methode de criblage de composes inhibiteurs de la mtp |
| JP5224707B2 (ja) * | 2005-04-28 | 2013-07-03 | 持田製薬株式会社 | 抗血小板膜糖蛋白質ｖｉモノクローナル抗体 |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| EP1876240B1 (en) * | 2005-04-28 | 2012-08-22 | Mochida Pharmaceutical Co., Ltd. | Anti-human platelet membrane glycoprotein vi monoclonal antibody |
| US20110045504A1 (en) * | 2005-12-22 | 2011-02-24 | Noriaki Kume | Prognostic Prediction Method for Acute Coronary Syndrome |
| EP2212416A4 (en) * | 2007-10-31 | 2013-01-09 | Otsuka Pharma Co Ltd | USE OF A GLYCOPROTEIN VI (GPVI) INHIBITOR |
| HUE027112T2 (en) * | 2008-12-04 | 2016-08-29 | Inserm (Institut Nat De La Sante Et De La Rech Medicale) | Procedure for producing platelets |
| ES2973099T3 (es) | 2009-05-15 | 2024-06-18 | Univ Health Network | Composiciones y procedimientos para el tratamiento de cánceres hematológicos dirigidos a la interacción entre SIRP alfa y CD47 |
| PL2513147T3 (pl) * | 2009-12-18 | 2017-08-31 | Sanofi | Nowe antagonistyczne przeciwciała i ich fragmenty Fab przeciwko GPVI i ich zastosowanie |
| EP2397495A1 (en) * | 2010-06-21 | 2011-12-21 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| EP2336188A1 (en) * | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| EP2377888A1 (en) * | 2010-04-07 | 2011-10-19 | Corimmun GmbH | Fusion protein |
| ES2755156T3 (es) | 2012-12-17 | 2020-04-21 | Trillium Therapeutics Inc | Tratamiento de células enfermas CD47+ con fusiones SIRP alfa-Fc |
| CA2895693C (en) * | 2012-12-20 | 2017-02-28 | Fujimori Kogyo Co., Ltd. | Method for comprehensive assessment of platelet aggregation |
| EP3424957A1 (en) | 2017-07-03 | 2019-01-09 | advanceCOR GmbH | Fusion protein |
| CN110964119A (zh) * | 2019-12-05 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 抗疟二聚体免疫粘附素、药物组合物和用途 |
| CN115768784A (zh) * | 2020-02-06 | 2023-03-07 | 勃林格殷格翰动物保健有限公司 | 用于检测抗弹状病毒抗体的多肽 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5156840A (en) * | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| ZA887365B (en) | 1987-10-02 | 1990-05-30 | Genentech Inc | Adheson variants |
| PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
| US6406697B1 (en) * | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5525491A (en) * | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| GB9806806D0 (en) | 1998-03-30 | 1998-05-27 | Univ Cambridge Tech | Peptides and uses thereof |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| GB9810999D0 (en) * | 1998-05-21 | 1998-07-22 | Goken Joop | Materials and methods relating to the expression of genes |
| AU775952B2 (en) | 1999-05-07 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use |
| US7291714B1 (en) * | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US20040001826A1 (en) | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US6245527B1 (en) * | 1999-06-30 | 2001-06-12 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof |
| AU7097400A (en) * | 1999-09-01 | 2001-03-26 | Otsuka Pharmaceutical Co., Ltd. | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof |
| EP1224942A1 (en) | 2001-01-23 | 2002-07-24 | Bernhard Dr. Nieswandt | Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
| PT2070939E (pt) | 2001-05-25 | 2014-06-09 | Univ Duke | Moduladores de agentes farmacológicos |
| EP1406929A2 (en) * | 2001-07-18 | 2004-04-14 | MERCK PATENT GmbH | Glycoprotein vi fusion proteins |
| GB0130543D0 (en) | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| GB0130832D0 (en) | 2001-12-22 | 2002-02-06 | Univ Reading | Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1) |
| GB0211750D0 (en) | 2002-05-22 | 2002-07-03 | Ouwehand Willem | Abnormal blood conditions |
| EP1538165A1 (en) | 2003-12-03 | 2005-06-08 | Procorde GmbH | Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4 |
| EP1369128A1 (en) | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| US7531178B2 (en) * | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
-
2002
- 2002-06-07 EP EP02012742A patent/EP1369128A1/en not_active Withdrawn
-
2003
- 2003-06-05 AU AU2003236704A patent/AU2003236704B2/en not_active Expired
- 2003-06-05 AT AT03735562T patent/ATE346095T1/de not_active IP Right Cessation
- 2003-06-05 SI SI200330640T patent/SI1511770T1/sl unknown
- 2003-06-05 CN CN038172798A patent/CN1668721B/zh not_active Expired - Lifetime
- 2003-06-05 CA CA2488630A patent/CA2488630C/en not_active Expired - Lifetime
- 2003-06-05 DK DK06023943.1T patent/DK1860118T3/en active
- 2003-06-05 WO PCT/EP2003/005929 patent/WO2003104282A2/en active IP Right Grant
- 2003-06-05 AU AU2003250825A patent/AU2003250825A1/en not_active Abandoned
- 2003-06-05 ES ES03735562T patent/ES2276078T3/es not_active Expired - Lifetime
- 2003-06-05 JP JP2004511349A patent/JP4722480B2/ja not_active Expired - Lifetime
- 2003-06-05 EP EP03735562A patent/EP1511770B1/en not_active Expired - Lifetime
- 2003-06-05 ES ES06023943.1T patent/ES2527717T3/es not_active Expired - Lifetime
- 2003-06-05 EP EP03757030A patent/EP1511480A2/en not_active Withdrawn
- 2003-06-05 US US10/489,053 patent/US7514543B2/en not_active Expired - Lifetime
- 2003-06-05 WO PCT/EP2003/005919 patent/WO2003103662A2/en not_active Application Discontinuation
- 2003-06-05 DE DE60309865T patent/DE60309865T2/de not_active Expired - Lifetime
- 2003-06-05 EP EP06023943.1A patent/EP1860118B1/en not_active Expired - Lifetime
-
2004
- 2004-12-02 ZA ZA200409776A patent/ZA200409776B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003104282A8 (en) | 2004-04-29 |
| EP1860118A3 (en) | 2008-07-30 |
| CN1668721A (zh) | 2005-09-14 |
| ZA200409776B (en) | 2007-02-28 |
| WO2003104282A3 (en) | 2004-10-14 |
| WO2003103662A2 (en) | 2003-12-18 |
| ATE346095T1 (de) | 2006-12-15 |
| WO2003103662A3 (en) | 2004-11-04 |
| AU2003236704B2 (en) | 2010-07-08 |
| WO2003104282A2 (en) | 2003-12-18 |
| EP1860118B1 (en) | 2014-12-31 |
| US20050079541A1 (en) | 2005-04-14 |
| DK1860118T3 (en) | 2015-02-09 |
| EP1511770A2 (en) | 2005-03-09 |
| JP2006512894A (ja) | 2006-04-20 |
| ES2276078T3 (es) | 2007-06-16 |
| DE60309865D1 (de) | 2007-01-04 |
| EP1369128A1 (en) | 2003-12-10 |
| CA2488630A1 (en) | 2003-12-18 |
| EP1860118A2 (en) | 2007-11-28 |
| US7514543B2 (en) | 2009-04-07 |
| DE60309865T2 (de) | 2007-10-18 |
| JP4722480B2 (ja) | 2011-07-13 |
| CA2488630C (en) | 2011-07-05 |
| AU2003250825A8 (en) | 2003-12-22 |
| EP1511770B1 (en) | 2006-11-22 |
| AU2003236704A1 (en) | 2003-12-22 |
| ES2527717T3 (es) | 2015-01-28 |
| EP1511480A2 (en) | 2005-03-09 |
| CN1668721B (zh) | 2012-11-14 |
| AU2003250825A1 (en) | 2003-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1511770T1 (sl) | Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni | |
| ME00185B (me) | Specifični agensi koji vezuju humani angiopoetin-2 | |
| DE60335552D1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
| ATE496063T1 (de) | Hybrid und tandemproteine von neisseria sp | |
| DK1144607T5 (da) | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger | |
| ATE455554T1 (de) | Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen | |
| ATE223229T1 (de) | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren | |
| SI1873166T1 (sl) | IZBOLJĹ ANI sgp 130Fc DIMERJI | |
| DE69534588D1 (de) | Protocadherin-proteine und verwendungen davon | |
| DE60320362D1 (de) | Verfahren zur Herstellung von Dipeptiden | |
| IL172729A0 (en) | Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins | |
| DE60215649D1 (de) | Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge | |
| ATE290088T1 (de) | Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms | |
| WO2003057719A3 (en) | Methods of modulating localization and physiological function of ip3 receptors | |
| ATE414164T1 (de) | Verfahren zur kontrolle der spaltung mit ompt protease | |
| ATE367438T1 (de) | Verfahren zur steigerung der expression von menschlichen tnf-rezeptor | |
| EP1467207A4 (en) | SCREENING PROCESS | |
| DE69810724D1 (de) | Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC) |